Skye Bioscience to host KOL event on CB1 Inhibition

Skye Bioscience announced that it will host a virtual KOL event entitled “Metabolic Rewiring with CB1 Inhibition” on Wednesday, July 24, 2024, at 9:00 AM ET. The KOL event will feature Louis J. Aronne, MD, FACP, Marcus DaSilva Goncalves, MD, PhD, Lee M. Kaplan, MD, PhD, and Beverly Tchang, MD, who will discuss the current treatment landscape for obesity, including the role of peripheral CB1 inhibition as a differentiated mechanism. The event will focus on the scientific rationale for Skye’s Nimacimab peripheral CB1 inhibitor, the clinical experience, and the Phase 2 study design for Nimacimab as a monotherapy and in combination with a GLP-1R agonist. Dosing for the Phase 2 trial is expected to begin in Q3 2024.